Methods of treating disorders using CSF1R inhibitors
Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising orally administering to the patient a therapeutically effective amount of the compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the tenosynovial giant cell tumor is diffuse-type tenosynovial giant cell tumor.
3. The method of claim 1 , wherein the tumor is benign.
4. The method of claim 1 , wherein administering comprises administering about 2 mg to about 60 mg of the compound daily, once a week, twice a week, or three times a week.
5. The method of claim 1 , wherein the administering comprises administering about 10 to about 90 mg of the compound daily, once a week, twice a week, or three times a week.
6. The method of claim 1 , wherein administering comprises
administering a loading dose of the compound daily for a first time period; and
administering a maintenance dose of the compound daily, twice weekly, or three times a week for a second time period.
7. The method of claim 6 , wherein the loading dose is about 10 to about 80 mg/day.
8. The method of claim 6 , wherein the loading dose is about 20 to about 60 mg/day.
9. The method of claim 6 , wherein the loading dose is about 20 mg, about 30 mg/day, about 40 mg/day, about 50 mg/day or about 60 mg/day.
10. The method of claim 6 , wherein the maintenance dose is about 2 mg to about 60 mg.
11. The method of claim 6 , wherein the maintenance dose is about 2 mg, about 10 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg or about 50 mg each administered twice or three times a week.
12. The method of claim 6 , wherein the first time period is about one or two weeks.
13. The method of claim 6 , wherein the first time period is about 4 days, about 5 days, about 6 days, or about 10 days.
14. The method of claim 6 , wherein the second time period is one month to about two months, three months or more.
15. The method of claim 6 , wherein the second time period is about one month to about nine months or more.
16. The method of claim 6 , further comprising administering an additional loading dose during a third time period.
17. The method of claim 16 , further comprising administering an additional maintenance dose during a fourth time period.
18. The method of claim 1 , wherein after 1 month or more of administration, the patient has an improved tumor response as measured by CT, Mill and/or RECIST.
19. The method of claim 1 , wherein after 1 month or more of administration, the patient has an improved range of motion.
20. The method of claim 1 , wherein after 1 month or more of administration, the patient has reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.
21. A method of treating a cancer selected from the group consisting of solid tumors, acute myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, and chronic lymphocytic leukemia, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one or a pharmaceutically acceptable salt thereof, wherein administering comprises:
administering a loading dose of the compound daily for a first time period; and
administering a maintenance dose of the compound daily, once a week, twice a week, or three times a week for a second time period.
22. The method of claim 21 , wherein the solid tumor is one of breast, cervix, pancreas, bladder, prostate, gastric, ovarian, melanoma, glioma, glioblastoma multiforme, osteosarcoma, osteolytic cancers, chondrosarcoma, histiocytosis, or lung cancer.
23. The method of claim 21 , wherein the solid tumor has progressed after prior administration of another cancer therapy.
24. The method of claim 21 , wherein the solid tumor is metastatic breast or prostate cancer with bone disease.
25. The method of claim 21 , wherein the solid tumor is gastric, ovarian or non-small cell lung cancer that has malignant associated ascites or effusion(s).
26. The method of claim 21 , further comprising administering another immunomodulatory therapeutic.
27. The method of claim 21 , further comprising administering a chemotherapeutic agent.
28. The method of claim 21 , further comprising administering an immunomodulatory therapeutic and another chemotherapeutic agent.
29. A method of treating tumors known to have expression of the receptor colony-stimulating factor 1 receptor (CSF1R) or its ligands, colony stimulating factor-1 (CSF1) or interleukin (IL)-34, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one or a pharmaceutically acceptable salt thereof, wherein administering comprises:
administering a loading dose of the compound daily for a first time period; and
administering a maintenance dose of the compound once a week, twice a week, or three times a week for a second time period.
30. The method of claim 29 , comprising determining if the tumor, its microenvironment, expresses CSF1R, CSF1, or IL-34 from the patient's extracted tumor sample, or patient's extracellular fluid.